Pharmaceutical Sector

Aurobindo Pharma shares surges 5% on bourses

Aurobindo PharmaThe announcement by Aurobindo Pharma to enter in to a strategic deal with US-based pharmaceutical major Pfizer helped its shares price on the Bombay Stock Exchange on Wednesday. The deal would allow selling of generic medicines, used for cardiovascular disease and central nervous system disorders, in the US and European market.

The global generic market is currently worth $270 billion and expected to grow over $500 billion in the next five years. Pfizer holds considerable shares in drug market, selling $10 billion non-exclusive drug annually.

US court ruling exposes drugmakers to lawsuits over warning labels

US court ruling exposes drugmakers to lawsuits over warning labels Washington  - The US Supreme Court ruled Wednesday that patients can sue drugmakers for failing to warn adequately of serious side effects, even if their warning labels were approved by the federal government, according to a landmark case that could expose the industry to billions of dollars in damages.

In a 6-3 decision, the court upheld a 7-million-dollar reward to a professional musician whose arm had to be amputated after she was improperly injected with Phenergan, an anti-nausea drug produced by pharmaceutical firm Wyeth.

Aurobindo Pharma Gets US FDA Tentative Approval To Market ‘Escitalopram’

Aurobindo Pharma Gets US FDA Tentative Approval To Market ‘Escitalopram’The US Food and Drug Administration (USFDA) has given tentative approval to Aurobindo Pharma, a Hyderabad-based manufacturer of generic pharmaceuticals and active pharmaceutical ingredients (APIs), to market Escitalopram Oxalate tablets in variable strengths.

Aurbindo will market the pills in dosages of 5mg, 10mg and 20mg.

Penta vaccines get high five from pharma players

Patient-friendliness, cost-savings make them attractive

Pfizer tilts to copycats with Aurobindo deal

Hyderabad-based drugmaker will license and supply 75 generic drugsthat address a $200m market to Pfizer

After trying it out for almost a year, the world's biggest drug-maker Pfizer Inc, has decided to turn copycat in right earnest. And the $50 billion giant will take the help of Hyderabad-based Aurobindo Pharma, an established copycat drug-maker, to make this happen.

The multinational will license 70 generic drugs and 12 sterile injectibles, including penicillins and cephalosporins, which according to industry watchers are valued at over $200 million in sales, from Aurobindo for marketing in the US, and Europe.

That is good news for Aurobindo but may not leave much for Pfizer to smile about, say analysts.

Pfizer tilts to copycats with Aurobindo deal

PfizerAfter trying it out for almost a year, the world's biggest drug-maker Pfizer Inc, has decided to turn copycat in right earnest. And the $50 billion giant will take the help of Hyderabad-based Aurobindo Pharma, an established copycat drug-maker, to make this happen. The multinational will license 70 generic drugs and 12 sterile injectibles, including penicillins and cephalosporins, which according to industry watchers are valued at over $200 million in sales, from Aurobindo for marketing in the US, and Europe. That is good news for Aurobindo but may not leave much for Pfizer to smile about, say analysts.

Pages